Anti-viral cytotoxic T cells inhibit the growth of cancer cells with antibody targeted HLA class I/peptide complexes in scid mice

International Journal of Cancer

Volumn 98, Issue 4, 2002, Pages 561-566

  Savage, Philip ^a,b   Cowburn, Pam ^b   Clayton, Aled ^b   Man, Stephen ^c   Lawson, Tom ^c   Ogg, Graham ^d   Lemoine, Nick ^e   McMichael, Andrew ^d   Epenetos, Agamemnon ^a,f  

^a Alexis Biotech Ltd   (United Kingdom)

^b VELINDRE CANCER CENTRE   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d MEDICAL RESEARCH COUNCIL   (United Kingdom)

^e HAMMERSMITH HOSPITAL   (United Kingdom)

^f ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Cancer; CTLs; HLA class I; Immunotherapy; Monoclonal antibody

Indexed keywords

ANTIBODY SPECIFICITY; ARTICLE; B CELL LYMPHOMA; COMBINED IMMUNODEFICIENCY; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; VACCINATION;

ANIMALS; ANTIBODIES; CELL DIVISION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; HLA ANTIGENS; HUMANS; MALE; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED; VIRUSES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0036533526     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10219     Document Type: Article

References (37)

1. Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens
2. Heterogeneous expression of the tumour-associated antigens RAGE-1, PRAME and glycoprotein 75 in human renal cell carcinoma: Candidates for T cell based immunotherapies?
3. Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an in vitro melanoma model
4. Preclinical and clinical data with bispecific antibodies recruiting myeloid effector cells for tumour therapy
5. Phase I study of single escalating doses of a superantigen-antibody fusion protein (PNU-214565) in patients with advanced colorectal or pancreatic carcinoma
6. Antibody-cytokine fusion proteins for the therapy of cancer
7. Sensitization of tumour cells to lysis by virus-specific CTL using antibody-targeted MHC class I/peptide complexes
8. Antibody-conjugated MHC class I tetramers can target tumour cells for specific lysis by T lymphocytes
9. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human lymphomas
10. Endocytosis and degradation of monoclonal antibodies targeting human B cell malignancies
11. Processing of antibodies bound to B cell lymphomas and other hematological malignancies
12. Rituximab as first line systemic therapy for patients with low-grade lymphoma
13. A tetravalent single-chain antibody-streptavidin fusion protein for pretargeted lymphoma therapy
14. Human cytotoxic CD8+ T-lymphocyte clones engraft in severe combined immunodeficient (SCID) mice but show diminished function
15. EBV-specific cytotoxic T lymphocytes protect against human EBV-associated lymphoma in SCID mice
16. A superantigen-antibody fusion protein for T cell immunotherapy of human B lineage malignancies
17. Combination immunotoxin treatment and chemotherapy in SCID mice with advanced, disseminated Daudi lymphoma
18. Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines
19. The alpha 1/alpha 2 domains of class I HLA molecules confer resistance to natural killing
20. Human tumour antigens recognized by T lymphocytes
21. The telomerase catalytic subunit is a widely expressed tumour-associated antigen recognized by cytotoxic T lymphocytes
22. Monoclonal antibodies in cancer therapy
23. Monoclonal antibody therapy for solid tumours
24. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies
25. Anti-CD20 and B cell receptor mediated apoptosis: Evidence for shared intracellular signaling pathways
26. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
27. Soluble HLA class I molecules induce apoptosis in alloreactive cytotoxic T lymphocytes
28. Purified truncated recombinant HLA-B7 molecules abrogate cell function in alloreactive cytotoxic T lymphocytes by apoptosis induction
29. In vitro induction of specific cytotoxic T lymphocytes using recombinant single-chain MHC class I/peptide complexes
30. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): Initial phase I/II study results
31. The 3-step pretargeting approach reduces the human anti-mouse antibody response in patients submitted to radioimmunoscintigraphy and radioimmunotherapy
32. Biochemical modifications of avidin improve pharmacokinetics and biodistribution and reduce immunogenicity
33. Recombinant anti-human melanoma antibodies are versatile molecules
34. + T cells specific for EBV in healthy virus carriers
35. 8+ T cells during the primary immune response to Epstein-Barr virus in vivo
36. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoprolfferative disease
37. The use of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus induced lymphoma in transplant recipients